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Abstract
Background: Persistent depressive disorder is prevalent, 
disabling, and often difficult to treat. The cognitive-behav-
ioral analysis system of psychotherapy (CBASP) is the only 
psychotherapy specifically developed for its treatment. 
However, we do not know which of CBASP, antidepressant 
pharmacotherapy, or their combination is the most effica-
cious and for which types of patients. This study aims to pres-
ent personalized prediction models to facilitate shared deci-
sion-making in treatment choices to match patients’ charac-
teristics and preferences based on individual participant 
data network metaregression. Methods: We conducted a 
comprehensive search for randomized controlled trials com-
paring any two of CBASP, pharmacotherapy, or their combi-
nation and sought individual participant data from identi-
fied trials. The primary outcomes were reduction in depres-
sive symptom severity for efficacy and dropouts due to any 
reason for treatment acceptability. Results: All 3 identified 
studies (1,036 participants) were included in the present 
analyses. On average, the combination therapy showed sig-
nificant superiority over both monotherapies in terms of ef-
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ficacy and acceptability, while the latter 2 treatments showed 
essentially similar results. Baseline depression, anxiety, prior 
pharmacotherapy, age, and depression subtypes moderat-
ed their relative efficacy, which indicated that for certain 
subgroups of patients either drug therapy or CBASP alone 
was a recommendable treatment option that is less costly, 
may have fewer adverse effects and match an individual pa-
tient’s preferences. An interactive web app (https://kokoro.
med.kyoto-u.ac.jp/CBASP/prediction/) shows the predicted 
disease course for all possible combinations of patient char-
acteristics. Conclusions: Individual participant data network 
metaregression enables treatment recommendations based 
on individual patient characteristics. © 2018 S. Karger AG, Basel
Introduction
Persistent depressive disorder refers to chronic forms 
of depression in which the depressed mood and associ-
ated symptoms persist for 2 years or more [1]. Persistent 
depressive disorder is a major public health problem ow-
ing to its frequency and its impact. In the general popula-
tion, it has an estimated lifetime prevalence of 3–6% [2]. 
Up to one third of individuals with acute depression de-
velops a chronic course [3]. When compared with acute 
episodic depression, persistent depression is associated 
with a greater rate of comorbid psychiatric disorders, 
greater social impairment and lower quality of life, more 
impaired physical health, and more frequent suicide at-
tempts and hospitalizations [4].
The past decades have seen some important advances 
in the pharmacological and psychological treatments of 
persistent depressive disorder. Even to this date however, 
it is often underrecognized and undertreated [5]. When 
treated, patient responses typically tend to be slow and 
poor with substantial residual symptoms [4]. Differential 
responses among the available treatments are insuffi-
ciently explored, and previous systematic reviews includ-
ing network meta-analyses concluded with different rec-
ommendations [6–9].
This confusion may be partly due to lumping together 
different forms of psychotherapies and also to application 
of different methodologies of evidence synthesis. For ex-
ample, older reviews included all forms of psychothera-
pies such as cognitive behavioral therapy or interperson-
al psychotherapy and could not reach clear conclusions 
[8, 9]. Two more recent reviews, by contrast, examined 
specific forms of psychotherapies but did not meta-ana-
lytically synthesize the available studies or explore possi-
ble sources of heterogeneity and instead based their rec-
ommendations on narrative review of the identified trials 
[6, 7]. The only specific psychotherapy that has been tai-
lored for chronic depression is the cognitive behavioral 
analysis system of psychotherapy (CBASP) [10]. The ini-
tial trial showed that it had comparable effects as antide-
pressant medication and significantly increased efficacy 
when combined with medication [11]. Subsequent trials 
have, however, shown mixed results [12, 13], and the rel-
ative efficacy of CBASP, antidepressant medication, or 
their combination, let alone their relative indications for 
particular patients, is yet to be clarified. A novel study is 
now warranted to synthesize the available evidence and 
explore the sources of reported heterogeneity in treat-
ment effects.
Providing the treatment that best fits each individual 
patient has always been an ideal practice in medicine [14]. 
One approach to this end, taken in personalized or preci-
sion medicine, is to find subgroups of patients who show 
a differential response based on their distinctive genetic, 
biological, or psychosocial characteristics [15]. After 
some pioneering work in finding subgroups for whom 
the average treatment effects may not apply [16], meth-
ods are now rapidly developing to explore possible sourc-
es of heterogeneity in treatment effects and to identify 
patient characteristics to guide differential therapeutics 
[17, 18]. 
A large body of high-quality data is needed to mean-
ingfully explore characteristics that should be accounted 
for when choosing an intervention. Meta-analysis offers 
a framework to synthesize evidence from multiple stud-
ies. When more than 2 treatment alternatives are avail-
able, network meta-analysis will take full advantage of the 
available data by comparing all treatments simultaneous-
ly and can elucidate the relative effectiveness among the 
competing alternatives. An increasingly large number of 
network meta-analyses has been published in the medical 
literature and in particular concerning mental health 
[19]. However, conventional meta-analysis of trial level 
summary data, either pairwise or in network, cannot 
properly assess the impact of individual characteristics. 
For this we need individual participant data. Individual 
participant data network meta-analysis (IPD-NMA) and 
meta-regression (IPD-NMR) based on all relevant clini-
cal trials enables a more powerful examination of the in-
fluence of both individual and group level characteristics 
and can optimally guide treatment decisions among the 
various treatment alternatives with the highest possible 
precision [20, 21]. There have been several pioneering 


















   
   
   
   
   
   
   
   
   
   
   

























work of pairwise or network meta-analyses in the past 2 
decades [21, 22], and important insights into the influ-
ence of individual-level characteristics have been ob-
tained. For example, baseline severity has been demon-
strated to moderate treatment response to antipsychotics 
in schizophrenia [23] and mania [24] (the greater the 
baseline severity, the larger the advantage of medication 
over placebo) but not for cognitive behavioral therapy for 
depression [25].
This study aims to conduct IPD-NMA and IPD-NMR 
to compare CBASP, antidepressant medication, and their 
combination among patients with persistent depressive 
disorder. The goal is to provide the tools that will enable 
differentiated, fine-tuned and informed treatment choic-
es for the patients, their families and their clinicians.
Methods
This systematic review has been registered in PROSPERO (reg-
istration No. CRD42016035886), and its full protocol has been 
published [26]. The reporting follows the PRISMA extension 
guideline for NMA [27].
Selection Criteria and Search Strategy
We sought all randomized controlled studies that compared 
any two of CBASP, antidepressant pharmacotherapy, or their 
combination in the treatment of patients with persistent depres-
sive disorder. 
Participants had to be men or women, aged 18 years or older, 
with persistent depressive disorder (DSM-5), chronic major de-
pression, recurrent major depression with incomplete interepi-
sode recovery or dysthymia (DSM-IV), or any corresponding con-
ditions according to standard diagnostic criteria. Studies in which 
all participants had a primary medical condition or a concurrent 
primary diagnosis of another mental disorder were excluded: a 
concurrent secondary diagnosis of another mental disorder was 
not considered an exclusion criterion.
Antidepressants could be any of the antidepressive agents li-
censed for the treatment of major depression in North America, 
Europe, or Japan.
We first conducted an electronic search of Cochrane CEN-
TRAL, PubMed, Scopus and PsycInfo, with the keywords: CBASP 
or “cognitive-behavioral analysis system of psychotherapy” and 
“depressive disorder.” We then sent the list of the identified trials 
to each study’s principal investigator to ask for further relevant tri-
als. We imposed no language restriction.
Data Collection and Assessment of Risk of Bias
We requested the principal investigators of the identified trials 
to provide us with the study protocol, assessment instruments used 
and individual participant data including the prespecified depen-
dent and independent variables (see below, patient, treatment, and 
trial characteristics).
We cross-examined the obtained data against the summary sta-
tistics (numbers and percentages, or means and standard devia-
tions) of the baseline demographic and clinical variables as report-
ed in the publications of each study. When the same or similar 
constructs were measured with different scales in the included 
studies, we standardized each construct according to the prespec-
ified rules (for details, see Table 1); once the data set was locked, 
the IPD-NMA and NMR were undertaken.
Two independent raters assessed the risk of bias in the includ-
ed studies using the tool described in the Cochrane Collaboration 
Handbook [28] as being at high risk of bias, low risk of bias, or 
unclear risk of bias in the following domains: generation of alloca-
tion sequence, allocation concealment, blinding of study person-
nel and participants, blinding of outcome assessor, attrition, selec-
tive outcome reporting, and other domains including sponsorship 
bias.
Outcomes 
Our primary outcomes were:
1. Depression severity as measured on a continuous observer-rat-
ed scale for depression. Where different scales such as the 
Montgomery-Asberg Depression Rating Scale or different ver-
sions of the Hamilton Rating Scale for Depression (HAM-D) 
were used, we transformed them into the 24-item HAM-D, us-
ing a conversion table based on the item response theory [29]
2. Dropouts for any reason, as a proxy measure of treatment ac-
ceptability
As deterioration on treatment is an often neglected yet clini-
cally important outcome [30, 31], we set as a secondary outcome:
3. Deterioration, defined as scoring above the baseline measure-
ment on a continuous observer-rated scale for depression
Patient, Treatment, and Trial Characteristics
We collected data on characteristics that can act as effect mod-
ifiers (EMs, variables that predict differential response to alterna-
tive treatments) and prognostic factors (PFs, variables that predict 
the overall course of a condition regardless of the treatments). We 




Life and Social History
2. Childhood maltreatment (emotional or physical abuse, neglect, 
sexual abuse)
3. Marital status (married, single, widowed/separated/divorced)
4. Social adjustment/function, as measured with global assess-
ment of functioning [33]
History of Present Illness
5. Age at onset
6. Length of current episode
7. Number of previous episodes
8. Prior treatments with antidepressants
9. Prior treatments with psychotherapies
Present Illness: Symptomatology
10. Subtype of chronic depression (chronic major depression, re-
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12. Baseline anxiety, based on anxiety/arousal factor of the Inven-
tory of Depressive Symptomatology Self-Report [34]
13. Comorbid personality disorder
Statistical Methods for Evidence Synthesis
We first synthesized data using IPD-NMA [20]. We combined 
information about multiple treatments and multiple outcomes 
measured at different time points. We developed a model that 
jointly synthesizes information on outcomes measured at multiple 
time points, while stochastically imputing missing outcome data 
assuming that they were missing at random. Due to the small num-
ber of identified studies per comparison, estimating heterogeneity 
in a random effects model was not feasible; fixed-effects models 
were employed in all analyses.
Table 1. Baseline demographic and clinical characteristics of the patients in the included studies
Variables Keller et al. [11], 2000 Kocsis et al. [12], 2009 Schramm et al. [39], 2015











mean SD mean SD mean SD
Age, years 43.3 10.7 45.1 12.5 43.6 10.6
Education, years – 15.4 3.1 11.6 1.8
Age at onset, years 26.8 13.1 26.2 12.8 –
Length of current episode, weeks 407 497 367 459 –
Baseline depression severity, 24-item HAM-D 26.9 5.0 19.2 8.2 26.2* 9.2
Baseline anxiety severity, IDS anxiety factor 13.8 4.6 8.6 4.9 14.4 4.9
Baseline functioning, global assessment of functioning 53.8 5.6 53.8 8.1 53.8 11.7
n % n % n %
Female sex 445 65.3 159 53.7 32 54.2
Employed – 176 60.0 39 70.0
Married 291 42.7 202 41.2 19 33.9
Depression diagnosis
Chronic MDD 239 35.1 110 37.2 9 15.3
Recurrent MDD without remission 154 22.6 88 29.7 13 22.0
Dysthymia 288 42.3 98 33.1 37 62.7
Prior use of medication 410 60.2 296 100 34 57.6
Prior use of psychotherapy 444 65.2 0 0 40 67.8
Personality disorder 240 35.3 – 24 40.7
History of abuse
Abuse 131** 19.4 39† 16.7 28‡ 47.5
Neglect 27** 4.0 43† 18.4 35‡ 59.3
Sexual abuse 111** 16.5 26† 10.9 9‡ 15.3
MDD, major depressive disorder; HAM-D, 24-item Hamilton Rating Scale for Depression; IDS, Inventory of Depressive 
Symptomatology Self-Report; CBASP, cognitive-behavioral analysis system of psychotherapy; MEDS, antidepressants; COMB, 
combination of cognitive-behavioral analysis system of psychotherapy + antidepressants. *  Converted from Montgomery-Asberg 
Depression Rating Scale into 24-item HAM-D, using the conversion table based on the item response theory [29]. ** Keller et al. [11], 
2000, used the Childhood Trauma Scale [40] and dichotomized it as presence/absence of abuse, neglect, and sexual abuse. † Kocsis [12], 
2009, used Measure of Parental Style (MOPS) [41], which provides maternal abuse and paternal abuse scores, based on 5 items, each 
rated between 0 = not true at all and 3 = extremely true. Abuse was judged present if either the maternal or paternal abuse score was >10. 
MOPS maternal indifference and paternal indifference scores are based on 6 items. Neglect was judged present if either the maternal or 
paternal indifference score was >12. Sexual abuse was judged present if the MOPS sexual abuse score >10 [41]. ‡ Schramm et al. [39], 
2015, used the Childhood Trauma Questionnaire (CTQ) [42]. The CTQ provides emotional abuse and physical abuse scores. If either 
was in the range “moderate to severe” or “severe to extreme,” abuse was judged present. The CTQ provides emotional neglect and 
physical neglect scores. If either was in the range “moderate to severe” or “severe to extreme,” neglect was judged present. The CTQ 


















   
   
   
   
   
   
   
   
   
   
   

























Consistency refers to the statistical agreement between direct 
and indirect estimates in the network and is a prerequisite of net-
work meta-analysis [35]. If consistency does not hold, network 
meta-analytic results may be biased. We evaluated statistical incon-
sistency using the design-by-treatment inconsistency model [36].
We then extended the model to an IPD-NMR by including in 
the model covariates that we identified as important EMs or PFs. 
To identify important covariates, we fitted a penalized regression 
model, using the glmnet package in R [37]. We only included co-
variates that were reported in all studies, and we performed mul-
tiple imputations for sporadically missing covariates. We explored 
first- and second-order combinations of these covariates, and their 
interactions with the treatment. In order to pinpoint which covari-
ates or treatment-covariate interactions to include in the model, 
we performed internal cross-validation. We fitted the model sepa-
rately in each multiply imputed data set, and we kept the terms that 
were selected by the penalized regression model in all data sets. 
Once a set of covariates is selected, we included them in a IPD-
NMR model and generated predictions for the disease course un-
der each treatment regime, given a set of patient characteristics. 
We created an interactive web application which accepts as inputs 
values for those characteristics selected as important in the model 
and generates the corresponding outcome predictions.
The models were fitted within a Bayesian framework using the 
OpenBUGS software [38] and vague priors for the relative treat-
ment effects. Online supplement 1 (for all online suppl. material, 
see www.karger.com/doi/10.1159/000489227) provides additional 
details of the statistical models and analyses performed. 
Results
Selection of Included Studies
The initial electronic search identified 671 references, 
from which 6 studies were identified as randomized con-
trolled trials involving CBASP. Inquiry with the principal 
investigators added 1 completed study. Of these, 3 studies 
[11, 12, 39] compared at least 2 of CBASP, antidepressant 
pharmacotherapy, or their combination in the treatment 
of patients with persistent depressive disorder. See online 
supplementary Figure S1 in the online supplement for the 
PRISMA flow diagram.
All the investigators agreed to collaborate with the 
present study and provided the requested protocols, rat-
ing scales, and data. The individual participant data for 
Kocsis et al. [12] were made available through the NIMH 
Data Repositories.
All the 3 studies were rated at low risk of bias in all the 
assessed domains, except for blinding of participants and 
personnel for which all 3 were at high risk of bias. The 
ratings were unanimous between the 2 independent rat-
ers.
Figure 1 presents the network structure of the 3 in-
cluded studies. Table 1 shows the baseline demographic 
and clinical characteristics of the participants. The pa-
tients were similar in terms of age, gender, age at onset, 
length of current episode or baseline social functioning. 
On the other hand, prior treatment differed among stud-
ies, mainly due to the study designs: in Kocsis et al. [12], 
patients were randomized to second-step pharmacother-
apy with or without CBASP after they had shown no or 
partial response to first-step pharmacotherapy. All par-
ticipants therefore had had prior pharmacotherapy when 
they entered the randomization phase and had relatively 
low depression and anxiety severity upon randomization. 
In Schramm et al. [39], patients with persistent depressive 
disorder were initially randomized to CBASP or to esci-
talopram but after 8 weeks of such acute-phase treatment, 
responders continued with the allocated treatment while 
nonresponders were augmented with the other treatment 
up to 20 weeks; the data from the initial randomized com-
parison were used in the present analysis, because the 
comparison after 8 weeks is no longer between CBASP 
and escitalopram per se. The online supplementary Table 
S1 tabulates data availability for depression severity by 
week for each study, and supplementary Figure S2 shows 
the pooled, aggregated raw HAM-D score changes of the 
participants allocated to each treatment.
Average Relative Treatment Effects: IPD-NMA
Table 2 shows the IPD-NMA results for the 2 primary 
outcomes (depression severity and dropouts for any rea-







Fig. 1. Network structure. CBASP, cognitive-behavioral analysis 
system of psychotherapy; MEDS, antidepressants; COMB, combi-
nation of cognitive-behavioral analysis system of psychotherapy + 
antidepressants. From Keller et al. [11], Kocsis et al. [12], and Sch-
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points but did not adjust for covariates. Thus, results refer 
to the whole population, on average. In this analysis, 
combination treatment emerged as the best treatment.
Relative Treatment Effects for Patients with Specific 
Characteristics: IPD-NMR
Table 3 shows the covariates (or combinations of co-
variates) which were selected as EMs and PFs for the 2 
primary outcomes, while online supplementary Tables S3 
and S4 provide parameter estimates for the selected co-
variates. The results indicate that the most influential co-
variate for depression severity was baseline HAM-D, 
which was selected both as PF and EM. Additional EMs 
included IDS anxiety factor and prior medication. For 
dropout, age and depression subtype also played a prom-
inent role.
Table 2. Average relative treatment effects for depression severity (in terms of points of improvement on the HAM-D) and dropout for 
any reason
Primary outcomes CBASP vs. COMB CBASP vs. MEDS MEDS vs. COMB
Mean difference in depression severity at 12 weeks 2.9 (1.3 to 4.6) 0.1 (–1.6 to 1.7) 2.9 (1.6 to 4.3)
Odds ratio for dropout for any reason at 12 weeks 1.57 (1.03 to 2.28) 0.97 (0.66 to 1.41) 1.59 (1.11 to 2.27)
A mean difference larger than zero for A vs. B means that patients in A have higher depression scores on average than those in B (B 
is a more efficacious treatment). An odds ratio larger than one for A vs. B means that patients in A have larger odds for dropouts (B is 
a more acceptable treatment). CBASP, cognitive-behavioral analysis system of psychotherapy; MEDS, antidepressants; COMB, combi-
nation of cognitive-behavioral analysis system of psychotherapy + antidepressants.
Table 3. Selected prognostic factors and effect modifiers for change in depression severity and dropout for any reason
Primary outcomes Prognostic factors Effect modifiers
CBASP vs. COMB MEDS vs. COMB




5. Neglect × HAM-D
6. HAM-D × prior medication
7. IDS anxiety factor × prior medication
1. (HAM-D)2
2. HAM-D × IDS anxiety 
factor
1. HAM-D
2. HAM-D × prior 
medication





6. Chronic MDD × HAM-D
7. Dysthymia × HAM-D
8. Age × marital status single
9. Age × chronic MDD
10. Marital status married ×prior medication
1. (Age)2
2. Age × chronic MDD
1. (HAM-D)2
2. Age × HAM-D
IDS anxiety factor, anxiety/arousal factor score of Inventory of Depressive Symptomatology Self-Report at baseline (continuous); 
HAM-D, 24-item Hamilton Rating Scale for depression score at baseline (continuous); prior medication, prior treatments with antide-
pressants (dichotomous); neglect, emotional or physical neglect (dichotomous); chronic MDD, chronic major depressive disorder (di-
chotomous); dysthymia, dysthymic disorder (dichotomous); marital status married, married/de facto/in a relationship (dichotomous); 
CBASP, cognitive-behavioral analysis system of psychotherapy; MEDS, antidepressants; COMB, combination of cognitive-behavioral 


















   
   
   
   
   
   
   
   
   
   
   

























Table 4 and Figure 2 show the average treatment effects 
and dropouts within specific patient subgroups as esti-
mated from the IPD-NMR model. As there is a large num-
ber of possible patient subgroups, in Table 4 we selected 5 
factors (depression severity, anxiety severity, prior medi-
cation, age, and depression subtype) to exemplify. The full 
interplay of all the identified EMs and PFs can be shown 
by an interactive web app (URL: https://kokoro.med.kyo-
to-u.ac.jp/CBASP/prediction/, illustrated in Fig. 2).
For patients with characteristics near the population 
averages (e.g. moderate baseline depression with moder-
ate anxiety [Fig. 2a], or low baseline depression with low 
anxiety), the relative treatment effects among the 3 arms 
are basically similar to the overall results shown in Table 
2: the combination treatment beats both CBASP alone or 
antidepressants alone by about 3 or 4 points (95% credi-
ble intervals, CrI: approx. 2–6) on the 24-item HAM-D, 
and there is no substantial difference between the latter 2 
(Table 4). In addition, the probability of dropping from 












Predicted differences in HAM-D 











patient age = 25 patient age = 60
CBASP COMB MEDS CBASP COMB MEDS












Dysthymia 42 51 36 24 25 27















Dysthymia 42 51 36 24 25 27















Dysthymia 36 45 50 19 21 31















Dysthymia 36 45 50 19 21 31













Chronic MDD 77 54 58 5 16 24
Recurrent MDD 25 32 36 12 13 21






Chronic MDD 67 41 55 3 10 17
– Chronic MDD 67 41 55 3 10 17
Recurrent MDD 25 32 46 12 13 21
95% credible intervals of predicted differences in HAM-D scores are shown in parentheses. The other effect modifiers and prognostic factors were set 
to: history of emotional or physical abuse = no, and marital status = single. CBASP, cognitive-behavioral analysis system of psychotherapy; MEDS, antide-


















   
   
   
   
   
   
   
   
   
   
   













































   
   
   
   
   
   
   
   
   
   
   

























treatment is estimated to be especially high (often > 50%) 
when patients are young and suffering from chronic ma-
jor depression; for other patients, the dropout probability 
estimates remain within expected ranges and may not 
cause concern for choosing treatments.
For patients with severe depression and anxiety (e.g. 
high baseline depression with high anxiety [Fig.  2b] or 
moderate baseline depression with high anxiety), the ad-
vantage of the combination treatment grows, beating the 
antidepressant alone by around 4–5 points (95% CrI: ap-
prox. 0–8), which then beats CBASP alone by another 4–5 
points (95% CrI: approx. –1 to 12) on the 24-item HAM-D 
(Table 4). However, the dropouts remain high both on the 
combination treatment and CBASP alone (> 50%) when 
the patient is young and has chronic major depression.
For patients with moderate baseline depression but 
with low anxiety (Fig. 2c), the relative treatment effects 
among the 3 alternative treatments change: both CBASP 
and the combination treatment beat the antidepressant 
alone treatment by 3–4 points (95%CrI: approx. 0–7), and 
there is no substantial difference between the former 
2 (Table 4). For young patients with chronic major de-
pression, the dropout rate on CBASP is extremely high 
(> 70%).
We also examined EMs and PFs to identify patients for 
whom the treatment was detrimental. While several fac-
tors in common with those for improvement were identi-
fied in variable selection, no strong evidence of effect 
modification was detected (online supplement 3, Tables 
S2 and S5).
Examination of Heterogeneity and Inconsistency
The design-by-treatment model provided no evidence 
of inconsistency. All inconsistency factors included in the 
model were found to be statistically nonsignificant (for 
details, see online supplement 4).
Discussion
We identified, and obtained individual participant 
data from, all 3 randomized controlled trials conducted 
to date comparing CBASP, antidepressant pharmaco-
therapy, or their combination for the treatment of persis-
tent depressive disorder (n = 1,036). IPD-NMA revealed 
robust superiority, on average, of the combination treat-
ment over CBASP alone or pharmacotherapy alone in 
terms of both efficacy and acceptability (approx. 3-point 
greater reduction on 24-item HAM-D or close to 40% 
lower odds of dropping out) and no substantive differ-
ence between CBASP alone or pharmacotherapy alone.
However, IPD-NMR allowed us to identify several po-
tent EMs and PFs to define subgroups of patients for 
whom these average results would not apply. For exam-
ple, patients with severe depression and severe anxiety 
would show symptom reduction in the distinctively de-
scending order of the combination, pharmacotherapy, 
and CBASP (combination is best) but dropouts from 
treatment in the clear ascending order of pharmacother-
apy, combination, and CBASP (pharmacotherapy is 
best), for example for young patients with chronic major 
depression; in such cases, pharmacotherapy may be a pre-
ferred option because the expected dropout on the com-
bination therapy is extremely high. By contrast, patients 
with moderate depression and mild anxiety would benefit 
equally well from the combination and CBASP alone but 
less from medication alone; here CBASP alone may be a 
preferred choice, as it is equally efficacious, less costly, 
and may match the patient’s preference.
The magnitude of difference between treatment groups 
and especially for specific subgroups was not only statisti-
cally significant but clinically meaningful. The minimally 
important change, i.e. the minimum within-person 
change in disease severity that patients would perceive as 
beneficial, has been found to be 3–5 points in the HAM-
D [44, 45]. The average between-group difference be-
tween the combination therapy and either monotherapy 
was approximately 3 points and is likely to be clinically 
meaningful (Table 2); for some subgroups of patients, the 
between-group difference may reach 9 points and is de-
finitively clinically important (Table 4).
The finding that some patients may not require drugs 
is clinically important because this will help them avoid 
unnecessary side effects including eventual withdrawal 
effects and iatrogenic aspects associated with long-term 
antidepressant treatment [31, 46, 47]. The finding that 
some other patients may derive comparable benefits 
without psychotherapy is also important, as it may lead 
Fig. 2. Interactive webpage for individual prediction of depression 
severity and risk to drop out (https://kokoro.med.kyoto-u.ac.jp/
CBASP/prediction/). a Patients with moderate baseline depression 
and moderate anxiety. b Patients with high baseline depression 
and high anxiety. c Patients with moderate baseline depression and 
low anxiety; In a–c, the other effect modifiers and prognostic fac-
tors were set to: age = 25, prior medication = no, history of emo-
tional or physical abuse = no, marital status = single, and primary 
diagnosis depression subtype = chronic major depression. For 
people who cannot access the website, the same functionality pro-
vided on an Excel sheet is available from the corresponding author 
upon request. CBASP, cognitive-behavioral analysis system of psy-
chotherapy; MEDS, antidepressants; COMB, combination of cog-
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to substantial reduction in costs both in terms of time 
and money. 
Our analyses identified the following 3 patient charac-
teristics to be the most prominent EMs for efficacy esti-
mates: baseline depression severity as measured with the 
24-item HAM-D, baseline anxiety severity as measured 
with IDS anxiety factor, and prior use of medication (Ta-
ble 3). Baseline depression severity has sometimes been 
noted as EM in the choice of treatments with psychother-
apy, pharmacotherapy, or their combination [48, 49] but 
not always [50]. Anxiety or some related characteristics 
have also been suggested to moderate the treatment effects 
in several studies [51, 52] but there are far fewer studies on 
the impact of anxiety in the treatment of depression. Prior 
drug treatment was found to be an EM in another study 
[53]. It is to note that, while all the included studies had 
recruited people with chronic depression, they differed in 
the proportion of those with prior exposure to pharmaco-
therapy. For example, in Kocsis et al. [12] all patients had 
had pharmacotherapy, and in Keller et al. [11] 60% did so, 
while in Schramm et al. [39] 24% of patients had had nei-
ther prior pharmacotherapy nor psychotherapy. This 
variability allowed IPD-NMR to identify prior medication 
history to be one of the EMs. It is also important not to 
equate chronicity with treatment resistance in the applica-
tion of the current prediction model.
Previous studies have suggested a number of other so-
ciodemographic and clinical variables as EMs in the 
choice of psychotherapy or medication for the treatment 
of depression, including age, marital status, employment 
status, childhood maltreatment, recent life events, or out-
patient treatment [53, 54]. We were unable to examine 
the effects of life events (not measured in any of the in-
cluded studies) or outpatient status (all included studies 
were conducted with outpatients) but for the remaining 
variables the effect was less pronounced and they were 
therefore not included in our final models. 
Of particular note, childhood maltreatment was not 
included as an EM but only as PF in our models. A sys-
tematic review has shown that childhood maltreatment 
can be both PF for overall poor prognosis and EM in the 
choice of pharmacotherapy or psychotherapy in depres-
sion treatments [55]. Previously, a secondary analysis 
from Keller et al. [11] indicated that among patients with-
out childhood trauma, the descending order of efficacy 
of treatment was combination, pharmacotherapy, and 
CBASP, while among those with childhood trauma, it was 
the combination, CBASP, and pharmacotherapy [56]. 
They concluded that CBASP was an essential element in 
the treatment of patients with persistent depressive disor-
der and a history of childhood trauma. When we com-
bined all relevant data and conducted IPD-NMR, physi-
cal or emotional neglect emerged as an important PF but 
was not included in the models as an EM. There may be 
several reasons for this apparent discrepancy between 
their findings and the current results. First, the 3 studies 
contributing to the current IPD-NMR measured child-
hood maltreatment with different measures (Table 1), 
which may have influenced the relationship between 
childhood trauma and the treatment effects in an unmea-
surable way. Second, the statistical analyses were different 
between theirs and our study. They applied the general 
linear model to the completers’ data while specifically fo-
cusing on the influence of childhood maltreatment. Our 
aim, however, was not to examine whether childhood 
maltreatment had a statistically significant effect on the 
relative effects but to build the best predictive model.
Our analysis identified several factors that may act as 
EMs and PFs to predict deterioration under treatment. 
However, the models overall were unable to detect strong 
effect modification. This was perhaps due to the small 
number of subjects who scored worse than their baseline 
in our data set: only some 10% of the patients showed de-
terioration after treatment. In the future, when we have 
assembled larger data sets, the current methodology can 
be expected to provide important insights in identifying 
participants likely to deteriorate under pharmacotherapy 
or psychotherapy [30, 31].
There are several weaknesses to our study. The biggest 
limitation, common to any reanalysis of available data, 
was that we were able to analyze only what was made 
available to us. Some studies did not measure the out-
comes important to our hypotheses (e.g. recent life events) 
or measured them differently (e.g. childhood maltreat-
ment). We conceptualized childhood maltreatment as 
presence/absence of abuse, neglect, and sexual abuses to 
both be consistent and retain as much information as 
possible across all the included studies. Secondly, we lim-
ited ourselves to CBASP, the only psychotherapy specifi-
cally developed for chronic depression, and thus do not 
know whether the current findings apply to other psycho-
therapies in the treatment of chronic or other depres-
sions. This specificity of our study, however, is also a 
strength: our current findings are clinically pertinent 
when we consider the treatment of persistent depressive 
disorder with CBASP. Thirdly, while focusing on CBASP, 
the included participants and the employed antidepres-
sants were heterogeneous. Medications were different 
among the 3 included studies (nefazodone, escitalopram, 


















   
   
   
   
   
   
   
   
   
   
   

























fazodone, that was used in the largest of the 3 trials [11], 
was withdrawn from the market for hepatotoxicity. The 
populations were variable, including those with estab-
lished antidepressant resistance to those naïve to pharma-
cotherapy or psychotherapy. There was, however, no sub-
stantive inconsistency in the network, and this variability 
allowed us to explore subgroup differences in the re-
sponse to 3 alternative treatments. Similar analyses are 
warranted in the future for more studies employing other 
types of antidepressants and other types of psychothera-
pies in order to further guide their individualized treat-
ments. Cross-methodological data synthesis from exper-
imental and observational studies including one-arm 
clinical trials, cohort data, and data from registries is an 
emerging area of research that can bridge the gap between 
evidence from well-controlled randomized trials in se-
lected patient groups and real-world evidence [57, 58].
It is to note that the statistical methods employed in our 
analysis did not break the internal comparisons of the 
studies. Both pairwise and network meta-analyses pre-
serve the randomization of the studies [59]. From each 
study a relative treatment effect is calculated separately at 
the first level (respecting randomization), and then study-
specific effects are synthesized at the second level. In this 
way, patients in one trial are not directly compared with 
patients in another trial. The use of regression at the IPD 
level and subgroup analyses equally preserve randomiza-
tion. Indirect comparison in NMA makes inferences 
about treatments which have not been directly compared. 
Although NMA and metaregression do respect the with-
in-study randomization, the evidence they provide can be 
viewed as nonrandomized because the treatment compar-
isons have not been randomized across the studies [60].
By contrast the strengths of our study may be summa-
rized as follows. First, we were able to identify and include 
all the individual participant data from the relevant ran-
domized controlled trials, which enabled us to conduct 
publication-bias-free reanalyses to make individual pre-
dictions. The study is free from data availability bias often 
seen in individual participant data analyses to date [61]. 
Second, the available data constituted a triangular net-
work of the 3 major competing treatments, to which we 
applied the network metaregression so that we were able 
to gain more power by combining direct and indirect 
comparisons, as compared to an ordinary, pairwise meta-
analysis. There was no detectable inconsistency in the in-
cluded studies, and we were able to make more precise 
effect estimates than in the original studies. Third, the rich 
IPD enabled us to apply the same imputation approach for 
missing data consistently across the included studies, 
while fully taking into account the repeated measure-
ments in the studies. Fourth, our analyses are more ad-
vanced than several previous attempts to synthesize the 
knowledge of the identified EMs and PFs in making indi-
vidual predictions of treatment effects [62, 63], because (i) 
we provide individual predictions simultaneously for 
more than 2 treatments, (ii) we model both efficacy and 
acceptability of the treatments, (iii) we use internal cross-
validation of single- and second-order EMs and PFs. The 
last feature has rarely been realized in the personalized 
treatment prediction models so far because all too often a 
sample size from a single study is relatively small [62], al-
though it has been repeatedly pointed out that using the 
whole data set as the derivation set risks overfitting the 
model to the data set and producing spurious and nonrep-
licable findings when building a prediction model [63, 64]. 
However, the true test of our model would call for an ex-
ternal validation study, ideally a randomized trial that in-
corporates the stratifications we have identified. Lastly, 
the resulting individualized prediction model allows for 
each patient’s values and preferences to play greater roles 
and some individuals to rightly opt for psychotherapy 
alone or pharmacotherapy alone. Such optimized and in-
dividualized decision-making would not only lead to 
greater patient satisfaction, but also substantial reduction 
in costs including time, money, efforts, and/or side effects.
In conclusion, the present study represents the first at-
tempt to build a personalized prediction model to facili-
tate shared decision-making when patients and their cli-
nicians discuss their treatment for persistent depressive 
disorder. We would encourage the use of our interactive 
web application (https://kokoro.med.kyoto-u.ac.jp/
CBASP/prediction/) when clinicians and patients discuss 
their options and choose the treatment that is most likely 
to bring about the desired outcomes, taking into account 
each patient’s individual characteristic such as age, base-
line depression severity, baseline anxiety severity, etc. The 
methodological implications of the current and similar 
studies may be far-reaching: days are probably gone when 
the blanket treatment recommendations based on group 
average were the best we could provide to our patients. 
We hope to see the development of similar interactive 
tools when viable alternative treatments exist for the same 
indication through collaborative sharing of individual 
clinical trial data. Ideally such efforts should share the 
common protocols so that data can be synthesized more 
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